Murata Fumiko, Maeda Megumi, Ishiguro Chieko, Fukuda Haruhisa
Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
Gen Psychiatr. 2022 Jun 20;35(3):e100802. doi: 10.1136/gpsych-2022-100802. eCollection 2022.
Characterising the psychiatric sequelae of coronavirus disease 2019 (COVID-19) can inform the development of long-term treatment strategies. However, few studies have examined these sequelae at different time points after COVID-19 infection.
The study aimed to investigate the incidences and risks of acute and delayed psychiatric sequelae in patients hospitalised with COVID-19 in Japan.
This retrospective cohort study was conducted using a database comprising healthcare claims data from public health insurance enrollees residing in a Japanese city. We analysed a primary cohort comprising patients hospitalised with COVID-19 between March 2020 and July 2021 and two control cohorts comprising patients hospitalised with influenza or other respiratory tract infections (RTI) during the same period. We calculated the incidences of acute (1-3 months after infection) and delayed (4-6 months after infection) psychiatric sequelae. These sequelae were identified using diagnosis codes and categorised as mood/anxiety/psychotic disorder, mood disorder, anxiety disorder, psychotic disorder or insomnia. Multivariable logistic regression models were used to estimate the odds ratios (ORs) of psychiatric sequelae occurrence after COVID-19 infection compared with influenza and other RTI.
The study population with acute psychiatric sequela consisted of 662 patients with COVID-19, 644 patients with influenza, and 7369 patients with RTI who could be followed for 3 months; the study population with delayed psychiatric sequelae consisted of 371 patients with COVID-19, 546 patients with influenza, and 5397 patients with RTI who could be followed for 6 months. In the analysis of acute psychiatric sequelae, COVID-19 had significantly higher odds of mood/anxiety/psychotic disorder (OR: 1.39, p=0.026), psychotic disorder (OR: 2.13, p<0.001), and insomnia (OR: 2.59, p<0.001) than influenza, and significantly higher odds of insomnia (OR: 1.44, p=0.002) and significantly lower odds of anxiety disorder (OR: 0.56, p<0.001) than other RTI. In the analysis of delayed psychiatric sequelae, COVID-19 had significantly higher odds of psychotic disorder (OR: 2.25, p=0.007) than influenza, but significantly lower odds of anxiety disorder (OR: 0.55, p=0.011) than other RTI.
COVID-19 was generally associated with an increased risk of psychiatric sequelae occurring within 3 months after infection, but had a lower risk of new psychiatric sequelae developing 4-6 months after infection.
对2019冠状病毒病(COVID-19)的精神后遗症进行特征描述可为长期治疗策略的制定提供依据。然而,很少有研究在COVID-19感染后的不同时间点对这些后遗症进行研究。
本研究旨在调查日本因COVID-19住院患者急性和延迟性精神后遗症的发生率及风险。
本回顾性队列研究使用了一个数据库,该数据库包含居住在日本一个城市的公共医疗保险参保者的医疗费用报销数据。我们分析了一个主要队列,该队列由2020年3月至2021年7月期间因COVID-19住院的患者组成,以及两个对照队列,这两个对照队列由同期因流感或其他呼吸道感染(RTI)住院的患者组成。我们计算了急性(感染后1 - 3个月)和延迟性(感染后4 - 6个月)精神后遗症的发生率。这些后遗症通过诊断编码进行识别,并分类为情绪/焦虑/精神病性障碍、情绪障碍、焦虑障碍、精神病性障碍或失眠。多变量逻辑回归模型用于估计与流感和其他RTI相比,COVID-19感染后发生精神后遗症的比值比(OR)。
患有急性精神后遗症的研究人群包括662例COVID-19患者、644例流感患者和7369例RTI患者,这些患者可随访3个月;患有延迟性精神后遗症的研究人群包括371例COVID-19患者、546例流感患者和5397例RTI患者,这些患者可随访6个月。在急性精神后遗症分析中,与流感相比,COVID-19发生情绪/焦虑/精神病性障碍(OR:1.39,p = 0.026)、精神病性障碍(OR:2.13,p < 0.001)和失眠(OR:2.59,p < 0.001)的几率显著更高,与其他RTI相比,发生失眠的几率显著更高(OR:1.44,p = 0.002),发生焦虑障碍的几率显著更低(OR:0.56,p < 0.001)。在延迟性精神后遗症分析中,与流感相比,COVID-19发生精神病性障碍的几率显著更高(OR:2.25,p = 0.007),但与其他RTI相比,发生焦虑障碍的几率显著更低(OR:0.55,p = 0.011)。
COVID-19通常与感染后3个月内发生精神后遗症的风险增加相关,但在感染后4 - 6个月出现新的精神后遗症的风险较低。